Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Morgan Stanley

Inception Portfolio Class I (MSSGX)

Ticker MSSGX · · Holdings as of Jun 30, 2026

Expense ratio
1%$100/yr per $10k
5-yr return
−4.5%annualized
1-yr return
+1.1%as of Dec 2025
Net assets
$282.2Mall share classes
Holdings
70

Bottom line

Is MSSGX a good fund? The bottom line

MSSGX is the Class I share class of Inception Portfolio, a managed large blend mutual fund from Morgan Stanley.

Annual fees run 1% — about $100 a year on every $10,000 invested, more expensive than 64% of large blend funds we track.

It returned +1.1% over one year, −4.5% a year over five years, +12.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $282 million in net assets and 70 holdings, its largest position is agilon health Inc (9.1%) and the top 10 make up 55.5% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 55.5% of assets

Updated Nov 19, 2026

What MSSGX invests in

The Inception Portfolio (the Fund) seeks long-term capital appreciation by investing primarily in growth-oriented equity securities of small capitalization companies.

Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in established and emerging companies with capitalizations within the range of companies included in the Russell 2000 Growth Index. As of December 31, 2025 , these market capitalizations ranged between $ 13.7 million and $ 26.0 billion. The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. In selecting securities for investment, the Adviser typically invests in unique companies it believes have sustainable competitive advantages with above average business visibility, the ability to deploy capital at high rates of return, strong balance sheets and an attractive risk/reward. The Adviser typically focuses a significant portion of the Funds investments in a limited number of issuers, which may be in the same…

From the fund's prospectus (filed Apr 30, 2026).

MSSGX performance

Fund calendar-year total returns, 2016–2025 2016: −0.4%; 2017: +21.9%; 2018: +0.3%; 2019: +37.1%; 2020: +150.6%; 2021: −3.3%; 2022: −59.4%; 2023: +54.4%; 2024: +29.6%; 2025: +1.1% −0% 2016 +22% 2017 +0% 2018 +37% 2019 +151% 2020 −3% 2021 −59% 2022 +54% 2023 +30% 2024 +1% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
MSSGX+1.1%−4.5%+12.8%
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full MSSGX performance history →

What MSSGX costs

On a $10,000 investment, MSSGX's 1% expense ratio costs about $100 a year. The prospectus estimates $1,426 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full MSSGX fee table →

MSSGX top 10 holdings

#Holding% of fund
1agilon health Inc9.10%
2Cloudflare Inc8.95%
3Opendoor Technologies Inc7.38%
4Aurora Innovation Inc6.57%
5IonQ Inc5.88%
6X4 Pharmaceuticals Inc3.82%
7HealthEquity Inc3.61%
8Celsius Holdings Inc3.53%
9Immunovant Inc3.44%
10GRAIL Inc3.19%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 55.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to MSSGX

More funds like MSSGX →

MSSGX FAQ

What is the expense ratio of MSSGX?
MSSGX's expense ratio is 1%, which works out to about $100 a year for every $10,000 invested. The prospectus estimates total costs of $1,426 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MSSGX a good investment?
It depends on your goals, but the data points to: no front-end sales load; 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 55.5% of assets. This is general information, not personalized advice.
What does MSSGX hold?
MSSGX's largest holdings are agilon health Inc (9.1%), Cloudflare Inc (8.9%), Opendoor Technologies Inc (7.4%), Aurora Innovation Inc (6.6%), IonQ Inc (5.9%). It holds 70 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MSSGX's 5-year return?
MSSGX returned −4.5% a year over the five years ending Dec 31, 2025, and +12.8% a year over ten years. Past performance does not guarantee future results.
Does MSSGX have a sales load?
No. MSSGX has no front-end sales charge.
Who manages MSSGX?
MSSGX is offered by Morgan Stanley through Morgan Stanley Institutional Fund Inc.